Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.525
-0.205 (-4.33%)
Sep 10, 2026, 1:02 PM EDT - Market open

Cytek Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-80.58-66.54-6.02-12.152.583.05
Depreciation & Amortization
11.911.9810.499.235.661.24
Loss (Gain) From Sale of Assets
0.360.420.060.01--
Asset Writedown & Restructuring Costs
-----0.28
Loss (Gain) From Sale of Investments
-5.12-5.67-5.21-6.66-0.08-
Loss (Gain) on Equity Investments
------0.04
Stock-Based Compensation
21.3724.5926.8522.0516.66.59
Provision & Write-off of Bad Debts
0.870.41-0.060.270.1-
Other Operating Activities
39.0134.93-8.433.052.842.15
Change in Accounts Receivable
4.880.37-5.43-7.33-19.74-12.37
Change in Inventory
-4.66-5.2414.764.29-17.65-7.07
Change in Accounts Payable
1.410.452.58-1.781.86-0.26
Change in Unearned Revenue
2.83.63.746.529.4110.01
Change in Other Net Operating Assets
1.72-3.97-7.93-12.2-13.81.03
Operating Cash Flow
-6.04-4.6925.385.28-12.234.63
Operating Cash Flow Growth
--380.57%---69.45%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-6.04-4.08-3.53-4.65-9.75-4.36
Sale of Property, Plant & Equipment
0.210.250.29---
Cash Acquisitions
---0.47-45.13--16.63
Sale (Purchase) of Intangibles
-0.09-0.11-0.2-0.18-0.12-
Investment in Securities
2.9514.06-79.06-43.94-46.04-
Other Investing Activities
-0-0----
Investing Cash Flow
-2.9810.12-82.97-93.89-55.91-20.99

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-5.584.18-2.98-
Total Debt Issued
8.625.584.18-2.98-
Short-Term Debt Repaid
------2.77
Long-Term Debt Repaid
--4.75-0.56-0.57-0.05-
Total Debt Repaid
-5.57-4.75-0.56-0.57-0.05-2.77
Net Debt Issued (Repaid)
3.050.843.62-0.572.93-2.77
Issuance of Common Stock
1.631.472.723.322.79216.33
Repurchase of Common Stock
-0.8-15.74-22.17-44.57-0.21-
Other Financing Activities
00----
Financing Cash Flow
3.88-13.43-15.82-41.815.51213.56

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
3.510.114.53-1.45-2.491.3
Net Cash Flow
-1.62-7.89-68.89-131.87-65.12198.5

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-12.08-8.7721.850.63-21.980.27
Free Cash Flow Growth
--3352.45%---98.05%
Free Cash Flow Margin
-5.84%-4.35%10.90%0.33%-13.40%0.21%
Free Cash Flow Per Share
-0.09-0.070.170.01-0.160.00
Levered Free Cash Flow
9.34.3337.88-1.34-23.76-6.21
Unlevered Free Cash Flow
9.494.6337.88-0.04-22.15-5.12

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
-2.163.835.3110.392.86
Change in Working Capital
6.15-4.797.71-10.51-39.93-8.65
SEC Filings: 10-K · 10-Q